Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $2.3 billion.

  • Revolution Medicines' Liabilities and Shareholders Equity rose 2773.23% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 2736.38%. This contributed to the annual value of $2.6 billion for FY2024, which is 2408.67% up from last year.
  • As of Q3 2025, Revolution Medicines' Liabilities and Shareholders Equity stood at $2.3 billion, which was up 2773.23% from $2.4 billion recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Liabilities and Shareholders Equity ranged from a high of $2.6 billion in Q4 2024 and a low of $632.8 million during Q2 2022
  • Over the past 5 years, Revolution Medicines' median Liabilities and Shareholders Equity value was $1.1 billion (recorded in 2023), while the average stood at $1.4 billion.
  • As far as peak fluctuations go, Revolution Medicines' Liabilities and Shareholders Equity tumbled by 1824.75% in 2022, and later soared by 15392.64% in 2023.
  • Over the past 5 years, Revolution Medicines' Liabilities and Shareholders Equity (Quarter) stood at $738.0 million in 2021, then increased by 10.02% to $811.9 million in 2022, then skyrocketed by 153.93% to $2.1 billion in 2023, then increased by 24.09% to $2.6 billion in 2024, then dropped by 11.98% to $2.3 billion in 2025.
  • Its Liabilities and Shareholders Equity was $2.3 billion in Q3 2025, compared to $2.4 billion in Q2 2025 and $2.4 billion in Q1 2025.